Purple Biotech (PPBT) Assets Average (2019 - 2021)

Purple Biotech (PPBT) has disclosed Assets Average for 3 consecutive years, with $77.0 million as the latest value for Q4 2021.

  • On a quarterly basis, Assets Average rose 56.31% to $77.0 million in Q4 2021 year-over-year; TTM through Dec 2021 was $77.0 million, a 56.31% increase, with the full-year FY2021 number at $77.0 million, up 56.31% from a year prior.
  • Assets Average was $77.0 million for Q4 2021 at Purple Biotech, up from $49.3 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $77.0 million in Q4 2021 to a low of $14.7 million in Q4 2019.
  • A 3-year average of $47.0 million and a median of $49.3 million in 2020 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: surged 234.64% in 2020, then surged 56.31% in 2021.
  • Purple Biotech's Assets Average stood at $14.7 million in 2019, then soared by 234.64% to $49.3 million in 2020, then soared by 56.31% to $77.0 million in 2021.
  • Per Business Quant, the three most recent readings for PPBT's Assets Average are $77.0 million (Q4 2021), $49.3 million (Q4 2020), and $14.7 million (Q4 2019).